Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,10543318,terminal half-life,"Following the repeated-dose regimen, the terminal half-life was not significantly different (2.7 (0.3) h) from that predicted from a single-dose (2.8 (0.2) h).",Single- and repeated-dose pharmacokinetics of intramuscular thiocolchicoside in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543318/),h,2.7,1373,DB01394,Colchicine
,10543318,terminal half-life,"Following the repeated-dose regimen, the terminal half-life was not significantly different (2.7 (0.3) h) from that predicted from a single-dose (2.8 (0.2) h).",Single- and repeated-dose pharmacokinetics of intramuscular thiocolchicoside in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543318/),h,2.8,1374,DB01394,Colchicine
,10543318,accumulation ratio,"The accumulation ratio, based on the repeated-dose/single-dose ratio of AUCtau was approximately 1.25.",Single- and repeated-dose pharmacokinetics of intramuscular thiocolchicoside in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543318/),,1.25,1375,DB01394,Colchicine
,10543318,CLT/f,"A decrease of CLT/f was found between day 1 (24.1 (5.2) l/h) and day 7 (19.9 (3.4) l/h), suggesting that moderate time-related alterations occur in the pharmacokinetics of thiocolchicoside, which may be due to a change in its CL(NR) (CL(R) was constant) or to the extent of bioavailability, explained by enterohepatic recirculation.",Single- and repeated-dose pharmacokinetics of intramuscular thiocolchicoside in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543318/),[l] / [h],24.1,1376,DB01394,Colchicine
,10543318,CLT/f,"A decrease of CLT/f was found between day 1 (24.1 (5.2) l/h) and day 7 (19.9 (3.4) l/h), suggesting that moderate time-related alterations occur in the pharmacokinetics of thiocolchicoside, which may be due to a change in its CL(NR) (CL(R) was constant) or to the extent of bioavailability, explained by enterohepatic recirculation.",Single- and repeated-dose pharmacokinetics of intramuscular thiocolchicoside in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10543318/),[l] / [h],19.9,1377,DB01394,Colchicine
,9387046,maximum tolerated dose,The maximum tolerated dose was 14.4 mg/m2.,A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9387046/),[mg] / [m2],14.4,1889,DB01394,Colchicine
,9387046,T1/2,"Mean pharmacokinetic parameter values: T1/2 = 5.52 hours, plasma clearance 1163 mL/min/m2, and Vdss 376 L/m2.",A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9387046/),h,5.52,1890,DB01394,Colchicine
,9387046,plasma clearance,"Mean pharmacokinetic parameter values: T1/2 = 5.52 hours, plasma clearance 1163 mL/min/m2, and Vdss 376 L/m2.",A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9387046/),[ml] / [m2·min],1163,1891,DB01394,Colchicine
,9387046,Vdss,"Mean pharmacokinetic parameter values: T1/2 = 5.52 hours, plasma clearance 1163 mL/min/m2, and Vdss 376 L/m2.",A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9387046/),[l] / [m2],376,1892,DB01394,Colchicine
,22753019,peak plasma concentration (C(max)),"There were no statistically significant (P < 0.05) differences in mean colchicine pharmacokinetic parameters between young and elderly subjects, including peak plasma concentration (C(max)) (2.53 vs. 2.56 ng/mL), time to C(max) (1.25 vs. 1.25 hours), area under the plasma concentration-time curve to infinity (22.29 vs. 25.01 ng/h/mL), elimination half-life (25.4 vs. 30.1 hours), oral clearance (0.40 vs. 0.35 L/h/kg), and apparent volume of distribution (14.3 vs. 14.8 L/kg), respectively.",Are dosing adjustments required for colchicine in the elderly compared with younger patients? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22753019/),[ng] / [ml],2.53,10656,DB01394,Colchicine
,22753019,peak plasma concentration (C(max)),"There were no statistically significant (P < 0.05) differences in mean colchicine pharmacokinetic parameters between young and elderly subjects, including peak plasma concentration (C(max)) (2.53 vs. 2.56 ng/mL), time to C(max) (1.25 vs. 1.25 hours), area under the plasma concentration-time curve to infinity (22.29 vs. 25.01 ng/h/mL), elimination half-life (25.4 vs. 30.1 hours), oral clearance (0.40 vs. 0.35 L/h/kg), and apparent volume of distribution (14.3 vs. 14.8 L/kg), respectively.",Are dosing adjustments required for colchicine in the elderly compared with younger patients? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22753019/),[ng] / [ml],2.56,10657,DB01394,Colchicine
,22753019,time to C(max),"There were no statistically significant (P < 0.05) differences in mean colchicine pharmacokinetic parameters between young and elderly subjects, including peak plasma concentration (C(max)) (2.53 vs. 2.56 ng/mL), time to C(max) (1.25 vs. 1.25 hours), area under the plasma concentration-time curve to infinity (22.29 vs. 25.01 ng/h/mL), elimination half-life (25.4 vs. 30.1 hours), oral clearance (0.40 vs. 0.35 L/h/kg), and apparent volume of distribution (14.3 vs. 14.8 L/kg), respectively.",Are dosing adjustments required for colchicine in the elderly compared with younger patients? ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22753019/),h,1.25,10658,DB01394,Colchicine
,22753019,area under the plasma concentration-time curve to infinity,"There were no statistically significant (P < 0.05) differences in mean colchicine pharmacokinetic parameters between young and elderly subjects, including peak plasma concentration (C(max)) (2.53 vs. 2.56 ng/mL), time to C(max) (1.25 vs. 1.25 hours), area under the plasma concentration-time curve to infinity (22.29 vs. 25.01 ng/h/mL), elimination half-life (25.4 vs. 30.1 hours), oral clearance (0.40 vs. 0.35 L/h/kg), and apparent volume of distribution (14.3 vs. 14.8 L/kg), respectively.",Are dosing adjustments required for colchicine in the elderly compared with younger patients? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22753019/),[ng] / [h·ml],22.29,10659,DB01394,Colchicine
,22753019,area under the plasma concentration-time curve to infinity,"There were no statistically significant (P < 0.05) differences in mean colchicine pharmacokinetic parameters between young and elderly subjects, including peak plasma concentration (C(max)) (2.53 vs. 2.56 ng/mL), time to C(max) (1.25 vs. 1.25 hours), area under the plasma concentration-time curve to infinity (22.29 vs. 25.01 ng/h/mL), elimination half-life (25.4 vs. 30.1 hours), oral clearance (0.40 vs. 0.35 L/h/kg), and apparent volume of distribution (14.3 vs. 14.8 L/kg), respectively.",Are dosing adjustments required for colchicine in the elderly compared with younger patients? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22753019/),[ng] / [h·ml],25.01,10660,DB01394,Colchicine
,22753019,elimination half-life,"There were no statistically significant (P < 0.05) differences in mean colchicine pharmacokinetic parameters between young and elderly subjects, including peak plasma concentration (C(max)) (2.53 vs. 2.56 ng/mL), time to C(max) (1.25 vs. 1.25 hours), area under the plasma concentration-time curve to infinity (22.29 vs. 25.01 ng/h/mL), elimination half-life (25.4 vs. 30.1 hours), oral clearance (0.40 vs. 0.35 L/h/kg), and apparent volume of distribution (14.3 vs. 14.8 L/kg), respectively.",Are dosing adjustments required for colchicine in the elderly compared with younger patients? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22753019/),h,25.4,10661,DB01394,Colchicine
,22753019,elimination half-life,"There were no statistically significant (P < 0.05) differences in mean colchicine pharmacokinetic parameters between young and elderly subjects, including peak plasma concentration (C(max)) (2.53 vs. 2.56 ng/mL), time to C(max) (1.25 vs. 1.25 hours), area under the plasma concentration-time curve to infinity (22.29 vs. 25.01 ng/h/mL), elimination half-life (25.4 vs. 30.1 hours), oral clearance (0.40 vs. 0.35 L/h/kg), and apparent volume of distribution (14.3 vs. 14.8 L/kg), respectively.",Are dosing adjustments required for colchicine in the elderly compared with younger patients? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22753019/),h,30.1,10662,DB01394,Colchicine
,22753019,oral clearance,"There were no statistically significant (P < 0.05) differences in mean colchicine pharmacokinetic parameters between young and elderly subjects, including peak plasma concentration (C(max)) (2.53 vs. 2.56 ng/mL), time to C(max) (1.25 vs. 1.25 hours), area under the plasma concentration-time curve to infinity (22.29 vs. 25.01 ng/h/mL), elimination half-life (25.4 vs. 30.1 hours), oral clearance (0.40 vs. 0.35 L/h/kg), and apparent volume of distribution (14.3 vs. 14.8 L/kg), respectively.",Are dosing adjustments required for colchicine in the elderly compared with younger patients? ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22753019/),[l] / [h·kg],0.40,10663,DB01394,Colchicine
,22753019,oral clearance,"There were no statistically significant (P < 0.05) differences in mean colchicine pharmacokinetic parameters between young and elderly subjects, including peak plasma concentration (C(max)) (2.53 vs. 2.56 ng/mL), time to C(max) (1.25 vs. 1.25 hours), area under the plasma concentration-time curve to infinity (22.29 vs. 25.01 ng/h/mL), elimination half-life (25.4 vs. 30.1 hours), oral clearance (0.40 vs. 0.35 L/h/kg), and apparent volume of distribution (14.3 vs. 14.8 L/kg), respectively.",Are dosing adjustments required for colchicine in the elderly compared with younger patients? ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22753019/),[l] / [h·kg],0.35,10664,DB01394,Colchicine
,22753019,apparent volume of distribution,"There were no statistically significant (P < 0.05) differences in mean colchicine pharmacokinetic parameters between young and elderly subjects, including peak plasma concentration (C(max)) (2.53 vs. 2.56 ng/mL), time to C(max) (1.25 vs. 1.25 hours), area under the plasma concentration-time curve to infinity (22.29 vs. 25.01 ng/h/mL), elimination half-life (25.4 vs. 30.1 hours), oral clearance (0.40 vs. 0.35 L/h/kg), and apparent volume of distribution (14.3 vs. 14.8 L/kg), respectively.",Are dosing adjustments required for colchicine in the elderly compared with younger patients? ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22753019/),[l] / [kg],14.3,10665,DB01394,Colchicine
,22753019,apparent volume of distribution,"There were no statistically significant (P < 0.05) differences in mean colchicine pharmacokinetic parameters between young and elderly subjects, including peak plasma concentration (C(max)) (2.53 vs. 2.56 ng/mL), time to C(max) (1.25 vs. 1.25 hours), area under the plasma concentration-time curve to infinity (22.29 vs. 25.01 ng/h/mL), elimination half-life (25.4 vs. 30.1 hours), oral clearance (0.40 vs. 0.35 L/h/kg), and apparent volume of distribution (14.3 vs. 14.8 L/kg), respectively.",Are dosing adjustments required for colchicine in the elderly compared with younger patients? ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22753019/),[l] / [kg],14.8,10666,DB01394,Colchicine
,29334816,AUC0-20,"By contrast, intravenous infusion of 0.25 mg/kg colchicine over 1 h produced reproducible pharmacokinetics (AUC0-20 343 [SD = 21] µg/L/h), acute multi-organ injury, and cardiotoxicity requiring euthanasia a mean of 22.5 (SD = 3.2) h after dosing.",Anti-colchicine Fab fragments prevent lethal colchicine toxicity in a porcine model: a pharmacokinetic and clinical study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29334816/),[μg] / [h·l],343,15586,DB01394,Colchicine
,29334816,AUC0-20,"A full-neutralising equimolar Fab dose given 6 h after the infusion (50% first hour, 50% next 6 h [to reduce renal-loss of unbound Fab]) produced a 7.35-fold increase in plasma colchicine (AUC0-20 2,522 [SD = 14] µg/L/h), and removed all free plasma colchicine, but did not prevent toxicity (euthanasia at 29.1 [SD = 3.4] h).",Anti-colchicine Fab fragments prevent lethal colchicine toxicity in a porcine model: a pharmacokinetic and clinical study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29334816/),[μg] / [h·l],"2,522",15587,DB01394,Colchicine
,29334816,AUC0-20,"Earlier administration over 1 h of the full-neutralising dose, 1 or 3 h after the colchicine, produced a 12.9-fold (AUC0-20 4,433 [SD = 607] µg/L/h) and 6.0-fold (AUC0-20 2,047 [SD = 51] µg/L/h) increase in plasma colchicine, respectively, absence of free plasma colchicine until 20 h, and survival to study end without marked cardiotoxicity.",Anti-colchicine Fab fragments prevent lethal colchicine toxicity in a porcine model: a pharmacokinetic and clinical study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29334816/),[μg] / [h·l],"4,433",15588,DB01394,Colchicine
,29334816,AUC0-20,"Earlier administration over 1 h of the full-neutralising dose, 1 or 3 h after the colchicine, produced a 12.9-fold (AUC0-20 4,433 [SD = 607] µg/L/h) and 6.0-fold (AUC0-20 2,047 [SD = 51] µg/L/h) increase in plasma colchicine, respectively, absence of free plasma colchicine until 20 h, and survival to study end without marked cardiotoxicity.",Anti-colchicine Fab fragments prevent lethal colchicine toxicity in a porcine model: a pharmacokinetic and clinical study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29334816/),[μg] / [h·l],"2,047",15589,DB01394,Colchicine
,21159616,MTD,The MTD was determined to be 3.3 mg/m(2) (0/13 patients had a DLT).,"Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21159616/),[mg] / [m(2],3.3,16341,DB01394,Colchicine
,21159616,Half-life,Half-life ranged from 3.8 to 7.5 hours.,"Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21159616/),h,3.8 to 7.5,16342,DB01394,Colchicine
,22913907,oral clearance,"Coadministration of cyclosporine increased colchicine maximum observed plasma concentration, area under the plasma concentration-time curve to the last measurable time point, and area under the plasma concentration-time curve to time infinity on average by 224%, 216%, and 215% (ie, almost doubled), respectively, and decreased colchicine oral clearance on average by 72% (from 48.24 to 13.42 L/h), indicating substantially higher colchicine exposures when combined with cyclosporine, compared with colchicine alone.",Effect of cyclosporine on the pharmacokinetics of colchicine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913907/),[l] / [h],48,18899,DB01394,Colchicine
,22913907,oral clearance,"Coadministration of cyclosporine increased colchicine maximum observed plasma concentration, area under the plasma concentration-time curve to the last measurable time point, and area under the plasma concentration-time curve to time infinity on average by 224%, 216%, and 215% (ie, almost doubled), respectively, and decreased colchicine oral clearance on average by 72% (from 48.24 to 13.42 L/h), indicating substantially higher colchicine exposures when combined with cyclosporine, compared with colchicine alone.",Effect of cyclosporine on the pharmacokinetics of colchicine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22913907/),[l] / [h],13,18900,DB01394,Colchicine
,2307399,clearance,The control group had a colchicine clearance of 77.33 ml/min.,The effect of liver dysfunction on colchicine pharmacokinetics in the rat. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2307399/),[ml] / [min],77.33,19267,DB01394,Colchicine
,2307399,half-life,"kg, a half-life of 16.68 min +/- 0.97 min and a volume of distribution of 1.84 L/kg +/- 0.15 L/kg.",The effect of liver dysfunction on colchicine pharmacokinetics in the rat. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2307399/),min,16.68,19268,DB01394,Colchicine
,2307399,volume of distribution,"kg, a half-life of 16.68 min +/- 0.97 min and a volume of distribution of 1.84 L/kg +/- 0.15 L/kg.",The effect of liver dysfunction on colchicine pharmacokinetics in the rat. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2307399/),[l] / [kg],1.84,19269,DB01394,Colchicine
,2307399,terminal half-life,"At 48 hr after bile duct ligation, colchicine clearance decreased by 84% (p less than 0.05), terminal half-life increased to 513.7 min +/- 106.6 min (p less than 0.05) and volume of distribution increased by 175% (p less than 0.05).",The effect of liver dysfunction on colchicine pharmacokinetics in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2307399/),min,513.7,19270,DB01394,Colchicine
,9874717,elimination half-lives,"The elimination half-lives were 52.9 and 81.8 h for cIgG and nIgG, respectively.",Pharmacokinetics and organ distribution of cationized colchicine-specific IgG and Fab fragments in rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9874717/),h,52.9,27323,DB01394,Colchicine
,9874717,elimination half-lives,"The elimination half-lives were 52.9 and 81.8 h for cIgG and nIgG, respectively.",Pharmacokinetics and organ distribution of cationized colchicine-specific IgG and Fab fragments in rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9874717/),h,81.8,27324,DB01394,Colchicine
,11448642,elimination half-life,"The elimination half-life of colchicine is 17h, suggesting that colchicne is disposable for long time.",Kinetics of micronucleus induction and cytotoxic activity of colchicine in murine erythroblast in vivo. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11448642/),h,17,31731,DB01394,Colchicine
,31196355,IC50,"H6 showed potent anti-proliferative ability with IC50 values from 7 to 47 nM, and remarkable ability to reduce tumor growth in several xenograft models including taxol resistant tumor models.","Anti-Tumor Study of H6, a 4-Substituted Coumarins Derivative, Loaded Biodegradable Self-Assembly Nano-Micelles In Vitro and In Vivo. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31196355/),nM,7 to 47,32409,DB01394,Colchicine
,31196355,drug loading,"The prepared H6/MPEG-PCL micelles had a drug loading of 3.79 ± 0.001%, an encapsulation efficiency of 98.00 ± 0.41%, a mean particle size of 30.45 ± 0.18nm and a polydispersity index (PDI) of 0.096 ± 0.009.","Anti-Tumor Study of H6, a 4-Substituted Coumarins Derivative, Loaded Biodegradable Self-Assembly Nano-Micelles In Vitro and In Vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31196355/),%,3.79,32410,DB01394,Colchicine
,31196355,encapsulation efficiency,"The prepared H6/MPEG-PCL micelles had a drug loading of 3.79 ± 0.001%, an encapsulation efficiency of 98.00 ± 0.41%, a mean particle size of 30.45 ± 0.18nm and a polydispersity index (PDI) of 0.096 ± 0.009.","Anti-Tumor Study of H6, a 4-Substituted Coumarins Derivative, Loaded Biodegradable Self-Assembly Nano-Micelles In Vitro and In Vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31196355/),%,98.00,32411,DB01394,Colchicine
,31196355,polydispersity index (PDI),"The prepared H6/MPEG-PCL micelles had a drug loading of 3.79 ± 0.001%, an encapsulation efficiency of 98.00 ± 0.41%, a mean particle size of 30.45 ± 0.18nm and a polydispersity index (PDI) of 0.096 ± 0.009.","Anti-Tumor Study of H6, a 4-Substituted Coumarins Derivative, Loaded Biodegradable Self-Assembly Nano-Micelles In Vitro and In Vivo. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31196355/),,0.096,32412,DB01394,Colchicine
,8009567,high-affinity constants,The three antisera presented similar high-affinity constants for colchicine of the order of 10(10) M-1.,Radioimmunoassay of colchicine with antisera exhibiting variable cross-reactivity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8009567/),1/[M],10(10),36286,DB01394,Colchicine
,8009567,limit of detection,The limit of detection of the three RIAs was 0.2 ng/ml.,Radioimmunoassay of colchicine with antisera exhibiting variable cross-reactivity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8009567/),[ng] / [ml],0.2,36287,DB01394,Colchicine
,23017885,IC(50),"In particular, we identified an analog (14), which exhibited a potent in vitro activity (IC(50): 5 nM) in MLR and excellent in vivo efficacy in the Zymosan A-induced arthritis model, in the Carrageenan-induced edema model and in the local lymph node assay (LLNA).",Part II. Development of novel colchicine-derived immunosuppressants with improved pharmacokinetic properties. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23017885/),nM,5,40914,DB01394,Colchicine
,23017885,oral bioavailability (F,Analog 14 also revealed a good oral bioavailability (F: 67.3%) in BALB/c mice.,Part II. Development of novel colchicine-derived immunosuppressants with improved pharmacokinetic properties. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23017885/),%,67.3,40915,DB01394,Colchicine
,2606428,Terminal half-life,"Terminal half-life (15.5-19.2 h), mean residence time (15.7-20.3 h), oral systemic (32.2-40.3 l/h) and renal (3.9-4.7 l/h) clearances, and oral volume of distribution (11.4-14.9 l/kg) did not differ significantly between doses, whereas the area under the concentration-time curve was proportional to dose.",Model-independent pharmacokinetics of colchicine after oral administration to healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2606428/),h,15.5-19.2,42082,DB01394,Colchicine
,2606428,mean residence time,"Terminal half-life (15.5-19.2 h), mean residence time (15.7-20.3 h), oral systemic (32.2-40.3 l/h) and renal (3.9-4.7 l/h) clearances, and oral volume of distribution (11.4-14.9 l/kg) did not differ significantly between doses, whereas the area under the concentration-time curve was proportional to dose.",Model-independent pharmacokinetics of colchicine after oral administration to healthy volunteers. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2606428/),h,15.7-20.3,42083,DB01394,Colchicine
,2606428,oral systemic,"Terminal half-life (15.5-19.2 h), mean residence time (15.7-20.3 h), oral systemic (32.2-40.3 l/h) and renal (3.9-4.7 l/h) clearances, and oral volume of distribution (11.4-14.9 l/kg) did not differ significantly between doses, whereas the area under the concentration-time curve was proportional to dose.",Model-independent pharmacokinetics of colchicine after oral administration to healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2606428/),[l] / [h],32.2-40.3,42084,DB01394,Colchicine
,2606428,renal,"Terminal half-life (15.5-19.2 h), mean residence time (15.7-20.3 h), oral systemic (32.2-40.3 l/h) and renal (3.9-4.7 l/h) clearances, and oral volume of distribution (11.4-14.9 l/kg) did not differ significantly between doses, whereas the area under the concentration-time curve was proportional to dose.",Model-independent pharmacokinetics of colchicine after oral administration to healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2606428/),[l] / [h],3.9-4.7,42085,DB01394,Colchicine
,2606428,oral volume of distribution,"Terminal half-life (15.5-19.2 h), mean residence time (15.7-20.3 h), oral systemic (32.2-40.3 l/h) and renal (3.9-4.7 l/h) clearances, and oral volume of distribution (11.4-14.9 l/kg) did not differ significantly between doses, whereas the area under the concentration-time curve was proportional to dose.",Model-independent pharmacokinetics of colchicine after oral administration to healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2606428/),[l] / [kg],11.4-14.9,42086,DB01394,Colchicine
,2815097,distribution half-life (t 1/2 a,A short distribution half-life (t 1/2 a = 34 min) is associated with a long elimination half-life (t1/2 beta = 48 h) together with a large volume of distribution at steady-state (Vss = 2.5 l/kg) and a low total body clearance (ClT = 1 ml/min/kg).,Influence of goat colchicine specific antibodies on murine colchicine disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815097/),min,34,48566,DB01394,Colchicine
,2815097,elimination half-life (t1/2 beta,A short distribution half-life (t 1/2 a = 34 min) is associated with a long elimination half-life (t1/2 beta = 48 h) together with a large volume of distribution at steady-state (Vss = 2.5 l/kg) and a low total body clearance (ClT = 1 ml/min/kg).,Influence of goat colchicine specific antibodies on murine colchicine disposition. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815097/),h,48,48567,DB01394,Colchicine
,2815097,volume of distribution at steady-state (Vss,A short distribution half-life (t 1/2 a = 34 min) is associated with a long elimination half-life (t1/2 beta = 48 h) together with a large volume of distribution at steady-state (Vss = 2.5 l/kg) and a low total body clearance (ClT = 1 ml/min/kg).,Influence of goat colchicine specific antibodies on murine colchicine disposition. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815097/),[l] / [kg],2.5,48568,DB01394,Colchicine
,2815097,total body clearance (ClT,A short distribution half-life (t 1/2 a = 34 min) is associated with a long elimination half-life (t1/2 beta = 48 h) together with a large volume of distribution at steady-state (Vss = 2.5 l/kg) and a low total body clearance (ClT = 1 ml/min/kg).,Influence of goat colchicine specific antibodies on murine colchicine disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2815097/),[ml] / [kg·min],1,48569,DB01394,Colchicine
,1449014,t1/2,Absorption is characterized by a zero-order rate constant while disposition appears biexponential with a rapid distribution phase (t1/2 = 1.8 h) and a long elimination phase (t1/2 = 20 h).,Pharmacokinetics of colchicine: a review of experimental and clinical data. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1449014/),h,1.8,48602,DB01394,Colchicine
,1449014,t1/2,Absorption is characterized by a zero-order rate constant while disposition appears biexponential with a rapid distribution phase (t1/2 = 1.8 h) and a long elimination phase (t1/2 = 20 h).,Pharmacokinetics of colchicine: a review of experimental and clinical data. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1449014/),h,20,48603,DB01394,Colchicine
,1449014,total body clearance,All studies confirm the large total body clearance (35 l/h) predominantly by the extrarenal route and the large distribution volume (700 l).,Pharmacokinetics of colchicine: a review of experimental and clinical data. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1449014/),[l] / [h],35,48604,DB01394,Colchicine
,1449014,distribution volume,All studies confirm the large total body clearance (35 l/h) predominantly by the extrarenal route and the large distribution volume (700 l).,Pharmacokinetics of colchicine: a review of experimental and clinical data. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1449014/),l,700,48605,DB01394,Colchicine
,16675578,MTD,The MTD for the q.d. schedule was 250 mg/d.,"The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16675578/),[mg] / [d],250,52996,DB01394,Colchicine
,16675578,MTD,The MTD on the b.i.d. schedule was 150 mg.,"The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16675578/),mg,150,52997,DB01394,Colchicine
,16675578,T(max),ABT-751 was absorbed after oral administration with an overall mean T(max) of about 2 hours.,"The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16675578/),h,2,52998,DB01394,Colchicine
,3882285,half-life,125I-labelled mouse SAP was cleared from the plasma in vivo with a half-life of 7.0-8.25 h in all animals studied including: normal mice of different strains with different genetically determined plasma SAP concentrations; mice undergoing acute phase responses with greatly elevated plasma SAP levels and mice with casein-induced amyloidosis.,Studies of the in vivo synthesis and catabolism of serum amyloid P component (SAP) in the mouse. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3882285/),h,7.0-8.25,54467,DB01394,Colchicine
,11808868,Tmax,"Pharmacokinetic parameters after administration of the test formulation were similar to those observed after administration of the reference (Tmax 0.50 (0.25-1.00) vs 0.50 (0.25-1.00), median and range; Cmax 115.5 +/- 26.6 vs 113.2 +/- 40.4 ng/ml; AUC 291.6 +/- 77.7 vs 283.3 +/- 98.9 ng.h/ml, means +/- SD).",Comparative bioavailability and tolerability study of two intramuscular formulations of thiocolchicoside in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808868/),,0.50,55496,DB01394,Colchicine
,11808868,Cmax,"Pharmacokinetic parameters after administration of the test formulation were similar to those observed after administration of the reference (Tmax 0.50 (0.25-1.00) vs 0.50 (0.25-1.00), median and range; Cmax 115.5 +/- 26.6 vs 113.2 +/- 40.4 ng/ml; AUC 291.6 +/- 77.7 vs 283.3 +/- 98.9 ng.h/ml, means +/- SD).",Comparative bioavailability and tolerability study of two intramuscular formulations of thiocolchicoside in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808868/),[ng] / [ml],115.5,55497,DB01394,Colchicine
,11808868,Cmax,"Pharmacokinetic parameters after administration of the test formulation were similar to those observed after administration of the reference (Tmax 0.50 (0.25-1.00) vs 0.50 (0.25-1.00), median and range; Cmax 115.5 +/- 26.6 vs 113.2 +/- 40.4 ng/ml; AUC 291.6 +/- 77.7 vs 283.3 +/- 98.9 ng.h/ml, means +/- SD).",Comparative bioavailability and tolerability study of two intramuscular formulations of thiocolchicoside in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808868/),[ng] / [ml],113.2,55498,DB01394,Colchicine
,11808868,AUC,"Pharmacokinetic parameters after administration of the test formulation were similar to those observed after administration of the reference (Tmax 0.50 (0.25-1.00) vs 0.50 (0.25-1.00), median and range; Cmax 115.5 +/- 26.6 vs 113.2 +/- 40.4 ng/ml; AUC 291.6 +/- 77.7 vs 283.3 +/- 98.9 ng.h/ml, means +/- SD).",Comparative bioavailability and tolerability study of two intramuscular formulations of thiocolchicoside in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808868/),[h·ng] / [ml],291.6,55499,DB01394,Colchicine
,11808868,AUC,"Pharmacokinetic parameters after administration of the test formulation were similar to those observed after administration of the reference (Tmax 0.50 (0.25-1.00) vs 0.50 (0.25-1.00), median and range; Cmax 115.5 +/- 26.6 vs 113.2 +/- 40.4 ng/ml; AUC 291.6 +/- 77.7 vs 283.3 +/- 98.9 ng.h/ml, means +/- SD).",Comparative bioavailability and tolerability study of two intramuscular formulations of thiocolchicoside in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808868/),[h·ng] / [ml],283.3,55500,DB01394,Colchicine
,11808868,Relative bioavailability (F),Relative bioavailability (F) was 1.05 +/- 0.13.,Comparative bioavailability and tolerability study of two intramuscular formulations of thiocolchicoside in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11808868/),,1.05,55501,DB01394,Colchicine
,1545388,Ka,High-affinity goat antibodies and Fab fragments (Ka = 1.1 x 10(10) M(-1) specific to colchicine were prepared to study their effect on colchicine pharmacokinetics in rabbits.,Colchicine-specific Fab fragments alter colchicine disposition in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545388/),1/[M],1.1 x 10(10),56004,DB01394,Colchicine
,1545388,elimination half-life,The mean elimination half-life of total plasma colchicine was 16 +/- 2.9 h.,Colchicine-specific Fab fragments alter colchicine disposition in rabbits. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545388/),h,16,56005,DB01394,Colchicine
,1545388,volume of distribution,Colchicine has a large volume of distribution (8.8 +/- 1.8 l/kg) and a low systemic clearance (114.6 +/- 3.4 ml.h-1.kg-1).,Colchicine-specific Fab fragments alter colchicine disposition in rabbits. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545388/),[l] / [kg],8.8,56006,DB01394,Colchicine
,1545388,systemic clearance,Colchicine has a large volume of distribution (8.8 +/- 1.8 l/kg) and a low systemic clearance (114.6 +/- 3.4 ml.h-1.kg-1).,Colchicine-specific Fab fragments alter colchicine disposition in rabbits. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1545388/),[ml] / [h·kg],114.6,56007,DB01394,Colchicine
<,16120068,trough concentrations,ATV trough concentrations exhibited substantial intersubject variability (<25-2108 microg l(-1)).,Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120068/),[μg] / [l],25-2108,64079,DB01394,Colchicine
,32614997,injection volume,"The injection volume and flow rate were 5.0 μl and 0.9 ml/min, respectively.",Simultaneous determination of colchicine and febuxostat in rat plasma: Application in a rat pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32614997/),μl,5.0,67681,DB01394,Colchicine
,32614997,flow rate,"The injection volume and flow rate were 5.0 μl and 0.9 ml/min, respectively.",Simultaneous determination of colchicine and febuxostat in rat plasma: Application in a rat pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32614997/),[ml] / [min],0.9,67682,DB01394,Colchicine
,2591469,lag time,"Considering the absorption variables as specific to each experiment, the lag time (0-0.35 h) and duration (0.39-2.38 h) of absorption were found to be independent of dose, while the zero-order rate constant of absorption (k0) increased linearly with dose.",Zero-order absorption and linear disposition of oral colchicine in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591469/),h,0-0.35,68684,DB01394,Colchicine
,2591469,terminal half-life,"For seven subjects the terminal half-life was 19.4 h, the oral apparent volume of distribution at steady-state (Vss/f) was 691 l, and the oral systemic clearance (CL/f) was 33.1 l.h-1.",Zero-order absorption and linear disposition of oral colchicine in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591469/),h,19.4,68685,DB01394,Colchicine
,2591469,oral apparent volume of distribution at steady-state (Vss/f),"For seven subjects the terminal half-life was 19.4 h, the oral apparent volume of distribution at steady-state (Vss/f) was 691 l, and the oral systemic clearance (CL/f) was 33.1 l.h-1.",Zero-order absorption and linear disposition of oral colchicine in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591469/),l,691,68686,DB01394,Colchicine
,2591469,oral systemic clearance (CL/f),"For seven subjects the terminal half-life was 19.4 h, the oral apparent volume of distribution at steady-state (Vss/f) was 691 l, and the oral systemic clearance (CL/f) was 33.1 l.h-1.",Zero-order absorption and linear disposition of oral colchicine in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591469/),[l] / [h],33.1,68687,DB01394,Colchicine
greater,2591469,terminal half-life,"In the two other subjects, the values were unreliable, but the estimated terminal half-life was greater than 48 h, Vss/f ranged from 1690 to 3480 l, and CL/f was in the range of the other subjects in 1 subject, and it was about 15 l.h-1 in the other.",Zero-order absorption and linear disposition of oral colchicine in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591469/),h,48,68688,DB01394,Colchicine
,2591469,Vss/f,"In the two other subjects, the values were unreliable, but the estimated terminal half-life was greater than 48 h, Vss/f ranged from 1690 to 3480 l, and CL/f was in the range of the other subjects in 1 subject, and it was about 15 l.h-1 in the other.",Zero-order absorption and linear disposition of oral colchicine in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591469/),l,1690 to 3480,68689,DB01394,Colchicine
,2591469,CL/f,"In the two other subjects, the values were unreliable, but the estimated terminal half-life was greater than 48 h, Vss/f ranged from 1690 to 3480 l, and CL/f was in the range of the other subjects in 1 subject, and it was about 15 l.h-1 in the other.",Zero-order absorption and linear disposition of oral colchicine in healthy volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2591469/),[l] / [h],15,68690,DB01394,Colchicine
,17931809,liver-to-blood distribution ratios (AUC(liver)/AUC(blood)),"The liver-to-blood distribution ratios (AUC(liver)/AUC(blood)) were 1.8+/-0.6, 1.0+/-0.2 and 0.8+/-0.1, and the bile-to-blood distribution ratios (AUC(bile)/AUC(blood)) were 121.6+/-24.7, 102.2+/-13.4 and 116.5+/-18.4 at dosages of 1, 3 and 10mg/kg, respectively.",Hepatobiliary excretion and enterohepatic circulation of colchicine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17931809/),,1.8,83368,DB01394,Colchicine
,17931809,liver-to-blood distribution ratios (AUC(liver)/AUC(blood)),"The liver-to-blood distribution ratios (AUC(liver)/AUC(blood)) were 1.8+/-0.6, 1.0+/-0.2 and 0.8+/-0.1, and the bile-to-blood distribution ratios (AUC(bile)/AUC(blood)) were 121.6+/-24.7, 102.2+/-13.4 and 116.5+/-18.4 at dosages of 1, 3 and 10mg/kg, respectively.",Hepatobiliary excretion and enterohepatic circulation of colchicine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17931809/),,1.0,83369,DB01394,Colchicine
,17931809,liver-to-blood distribution ratios (AUC(liver)/AUC(blood)),"The liver-to-blood distribution ratios (AUC(liver)/AUC(blood)) were 1.8+/-0.6, 1.0+/-0.2 and 0.8+/-0.1, and the bile-to-blood distribution ratios (AUC(bile)/AUC(blood)) were 121.6+/-24.7, 102.2+/-13.4 and 116.5+/-18.4 at dosages of 1, 3 and 10mg/kg, respectively.",Hepatobiliary excretion and enterohepatic circulation of colchicine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17931809/),,0.8,83370,DB01394,Colchicine
,17931809,bile-to-blood distribution ratios (AUC(bile)/AUC(blood)),"The liver-to-blood distribution ratios (AUC(liver)/AUC(blood)) were 1.8+/-0.6, 1.0+/-0.2 and 0.8+/-0.1, and the bile-to-blood distribution ratios (AUC(bile)/AUC(blood)) were 121.6+/-24.7, 102.2+/-13.4 and 116.5+/-18.4 at dosages of 1, 3 and 10mg/kg, respectively.",Hepatobiliary excretion and enterohepatic circulation of colchicine in rats. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17931809/),,121.6,83371,DB01394,Colchicine
,17931809,bile-to-blood distribution ratios (AUC(bile)/AUC(blood)),"The liver-to-blood distribution ratios (AUC(liver)/AUC(blood)) were 1.8+/-0.6, 1.0+/-0.2 and 0.8+/-0.1, and the bile-to-blood distribution ratios (AUC(bile)/AUC(blood)) were 121.6+/-24.7, 102.2+/-13.4 and 116.5+/-18.4 at dosages of 1, 3 and 10mg/kg, respectively.",Hepatobiliary excretion and enterohepatic circulation of colchicine in rats. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17931809/),,102.2,83372,DB01394,Colchicine
,17931809,bile-to-blood distribution ratios (AUC(bile)/AUC(blood)),"The liver-to-blood distribution ratios (AUC(liver)/AUC(blood)) were 1.8+/-0.6, 1.0+/-0.2 and 0.8+/-0.1, and the bile-to-blood distribution ratios (AUC(bile)/AUC(blood)) were 121.6+/-24.7, 102.2+/-13.4 and 116.5+/-18.4 at dosages of 1, 3 and 10mg/kg, respectively.",Hepatobiliary excretion and enterohepatic circulation of colchicine in rats. ,Css ratio-Q35,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17931809/),,116.5,83373,DB01394,Colchicine
,27436437,initial,"His initial and peak apixaban concentration was 1022.6 ng/ml and was associated with only minor bleeding from his femoral central line insertion site, which improved with local compression.",Anti-Xa activity in apixaban overdose: a case report. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436437/),[ng] / [ml],1022.6,86365,DB01394,Colchicine
,27436437,peak apixaban concentration,"His initial and peak apixaban concentration was 1022.6 ng/ml and was associated with only minor bleeding from his femoral central line insertion site, which improved with local compression.",Anti-Xa activity in apixaban overdose: a case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436437/),[ng] / [ml],1022.6,86366,DB01394,Colchicine
,27436437,elimination half-life,Apixaban elimination appeared to display first-order kinetics with an elimination half-life of 7.4 h.,Anti-Xa activity in apixaban overdose: a case report. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27436437/),h,7.4,86367,DB01394,Colchicine
,7389258,elimination half-life (t1/2),Mean elimination half-life (t1/2) (+/- SEM) was 157 +/- 20 min in the patients and 65 +/- 15 min in the normal subjects (p less than 0.005).,Colchicine kinetics in patients with familial Mediterranean fever. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389258/),min,157,93694,DB01394,Colchicine
,7389258,elimination half-life (t1/2),Mean elimination half-life (t1/2) (+/- SEM) was 157 +/- 20 min in the patients and 65 +/- 15 min in the normal subjects (p less than 0.005).,Colchicine kinetics in patients with familial Mediterranean fever. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389258/),min,65,93695,DB01394,Colchicine
,7389258,Total clearance,Total clearance was 239 +/- 50 ml/min in the patients and 601 +/- 155 ml/min in the normal subjects (p less than 0.05).,Colchicine kinetics in patients with familial Mediterranean fever. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389258/),[ml] / [min],239,93696,DB01394,Colchicine
,7389258,Total clearance,Total clearance was 239 +/- 50 ml/min in the patients and 601 +/- 155 ml/min in the normal subjects (p less than 0.05).,Colchicine kinetics in patients with familial Mediterranean fever. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389258/),[ml] / [min],601,93697,DB01394,Colchicine
,7389258,Volume of distribution (Vdarea),Volume of distribution (Vdarea) was 76 +/- 16 and 49 +/- 91 and did not differ significantly.,Colchicine kinetics in patients with familial Mediterranean fever. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389258/),,76,93698,DB01394,Colchicine
,7389258,Volume of distribution (Vdarea),Volume of distribution (Vdarea) was 76 +/- 16 and 49 +/- 91 and did not differ significantly.,Colchicine kinetics in patients with familial Mediterranean fever. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7389258/),,49,93699,DB01394,Colchicine
,1361548,volume of distribution,"The plasma disposition was characterized by a volume of distribution of 179 +/- 48 mL kg-1, total body clearance of 1.02 +/- 0.07 mL min-1 kg-1, t1/2 alpha of 0.17 +/- 0.03 h and t1/2 beta of 1.3 +/- 0.3 h.",Fab-bound colchicine appears to adopt Fab fragment disposition in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361548/),[ml] / [kg],179,102131,DB01394,Colchicine
,1361548,total body clearance,"The plasma disposition was characterized by a volume of distribution of 179 +/- 48 mL kg-1, total body clearance of 1.02 +/- 0.07 mL min-1 kg-1, t1/2 alpha of 0.17 +/- 0.03 h and t1/2 beta of 1.3 +/- 0.3 h.",Fab-bound colchicine appears to adopt Fab fragment disposition in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361548/),[ml] / [kg·min],1.02,102132,DB01394,Colchicine
,1361548,t1/2 alpha,"The plasma disposition was characterized by a volume of distribution of 179 +/- 48 mL kg-1, total body clearance of 1.02 +/- 0.07 mL min-1 kg-1, t1/2 alpha of 0.17 +/- 0.03 h and t1/2 beta of 1.3 +/- 0.3 h.",Fab-bound colchicine appears to adopt Fab fragment disposition in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361548/),h,0.17,102133,DB01394,Colchicine
,1361548,t1/2 beta,"The plasma disposition was characterized by a volume of distribution of 179 +/- 48 mL kg-1, total body clearance of 1.02 +/- 0.07 mL min-1 kg-1, t1/2 alpha of 0.17 +/- 0.03 h and t1/2 beta of 1.3 +/- 0.3 h.",Fab-bound colchicine appears to adopt Fab fragment disposition in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361548/),h,1.3,102134,DB01394,Colchicine
,1361548,fraction of,The fraction of colchicine dose excreted by the urinary route was 38 +/- 6.9 and 9 +/- 0.7% respectively in Fab-colchicine- and colchicine-treated groups (P < 0.01).,Fab-bound colchicine appears to adopt Fab fragment disposition in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361548/),%,38,102135,DB01394,Colchicine
,1361548,fraction of,The fraction of colchicine dose excreted by the urinary route was 38 +/- 6.9 and 9 +/- 0.7% respectively in Fab-colchicine- and colchicine-treated groups (P < 0.01).,Fab-bound colchicine appears to adopt Fab fragment disposition in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361548/),%,9,102136,DB01394,Colchicine
,1959847,clearance,Normal subjects had a mean clearance of 10.65 +/- 1.82 ml/min.,Colchicine clearance is impaired in alcoholic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1959847/),[ml] / [min],10.65,104919,DB01394,Colchicine
,1959847,clearance,"kg, whereas cirrhotic patients had a mean clearance of 4.22 +/- 0.45 ml/min.kg (p less than 0.01).",Colchicine clearance is impaired in alcoholic cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1959847/),[ml] / [kg·min],4.22,104920,DB01394,Colchicine
,1959847,half-life,The half-life was 57.4 +/- 14.2 min in control subjects vs. 114.4 +/- 19.7 min in cirrhotic patients (p = 0.054).,Colchicine clearance is impaired in alcoholic cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1959847/),min,57.4,104921,DB01394,Colchicine
,1959847,half-life,The half-life was 57.4 +/- 14.2 min in control subjects vs. 114.4 +/- 19.7 min in cirrhotic patients (p = 0.054).,Colchicine clearance is impaired in alcoholic cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1959847/),min,114.4,104922,DB01394,Colchicine
,1959847,Volume of distribution,"Volume of distribution was not different in the two groups (0.718 +/- 0.1 L/kg in control subjects; 0.716 +/- 0.158 L/kg in cirrhotic patients, p greater than 0.99).",Colchicine clearance is impaired in alcoholic cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1959847/),[l] / [kg],0.718,104923,DB01394,Colchicine
,1959847,Volume of distribution,"Volume of distribution was not different in the two groups (0.718 +/- 0.1 L/kg in control subjects; 0.716 +/- 0.158 L/kg in cirrhotic patients, p greater than 0.99).",Colchicine clearance is impaired in alcoholic cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1959847/),[l] / [kg],0.716,104924,DB01394,Colchicine
,1959847,steady state,"Based on the values measured, it is estimated that colchicine steady state would change from an average 1.12 ng/ml in normal individuals to 2.82 ng/ml in the cirrhotic patients if 0.6 mg were taken every 12 hr.",Colchicine clearance is impaired in alcoholic cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1959847/),[ng] / [ml],1.12,104925,DB01394,Colchicine
,1959847,steady state,"Based on the values measured, it is estimated that colchicine steady state would change from an average 1.12 ng/ml in normal individuals to 2.82 ng/ml in the cirrhotic patients if 0.6 mg were taken every 12 hr.",Colchicine clearance is impaired in alcoholic cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1959847/),[ng] / [ml],2.82,104926,DB01394,Colchicine
,17187251,terminal half-life,Plasma disappearance was bi-exponential with a terminal half-life of 13 h.,Plasma and cerebrospinal fluid pharmacokinetics of intravenously administered ABT-751 in non-human primates. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17187251/),h,13,107931,DB01394,Colchicine
,17187251,clearance,"The mean +/- SD clearance was 100 +/- 18 ml/min m2, the mean +/- SD volume of distribution at steady state was 1.3 +/- 0.5 l/kg, and the mean +/- SD mean residence time was 4.6 +/- 1.8 h.",Plasma and cerebrospinal fluid pharmacokinetics of intravenously administered ABT-751 in non-human primates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17187251/),[ml] / [m2·min],100,107932,DB01394,Colchicine
,17187251,volume of distribution at steady state,"The mean +/- SD clearance was 100 +/- 18 ml/min m2, the mean +/- SD volume of distribution at steady state was 1.3 +/- 0.5 l/kg, and the mean +/- SD mean residence time was 4.6 +/- 1.8 h.",Plasma and cerebrospinal fluid pharmacokinetics of intravenously administered ABT-751 in non-human primates. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17187251/),[l] / [kg],1.3,107933,DB01394,Colchicine
,17187251,mean residence time,"The mean +/- SD clearance was 100 +/- 18 ml/min m2, the mean +/- SD volume of distribution at steady state was 1.3 +/- 0.5 l/kg, and the mean +/- SD mean residence time was 4.6 +/- 1.8 h.",Plasma and cerebrospinal fluid pharmacokinetics of intravenously administered ABT-751 in non-human primates. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17187251/),h,4.6,107934,DB01394,Colchicine
,17187251,peak ABT-751 concentration,"The mean +/- SD peak ABT-751 concentration in CSF was 0.26 +/- 0.08 microM, and the mean +/- SD CSF half-life of 1.3 +/- 0.3 h.",Plasma and cerebrospinal fluid pharmacokinetics of intravenously administered ABT-751 in non-human primates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17187251/),μM,0.26,107935,DB01394,Colchicine
,17187251,half-life,"The mean +/- SD peak ABT-751 concentration in CSF was 0.26 +/- 0.08 microM, and the mean +/- SD CSF half-life of 1.3 +/- 0.3 h.",Plasma and cerebrospinal fluid pharmacokinetics of intravenously administered ABT-751 in non-human primates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17187251/),h,1.3,107936,DB01394,Colchicine
,8585121,Cross-reactivity,"Cross-reactivity was 56% for TC, giving a limit of quantification of 0.5 ng/ml and a linear response from 0.5 to 100 ng/ml.",Pharmacokinetics of thiocolchicoside in humans using a specific radioimmunoassay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8585121/),%,56,117834,DB01394,Colchicine
,8585121,Vss,Pharmacokinetics of TC following infusion of 4 mg in two subjects revealed a moderate distribution (Vss from 31 to 35 L) and mainly extrarenal elimination (75% of the total body clearance).,Pharmacokinetics of thiocolchicoside in humans using a specific radioimmunoassay. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8585121/),l,31 to 35,117835,DB01394,Colchicine
,8585121,Terminal half-lives,Terminal half-lives ranged from 2.4 to 2.7 h in plasma and from 3.2 to 3.7 h in urine.,Pharmacokinetics of thiocolchicoside in humans using a specific radioimmunoassay. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8585121/),h,2.4 to 2.7,117836,DB01394,Colchicine
,8585121,Terminal half-lives,Terminal half-lives ranged from 2.4 to 2.7 h in plasma and from 3.2 to 3.7 h in urine.,Pharmacokinetics of thiocolchicoside in humans using a specific radioimmunoassay. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8585121/),h,3.2 to 3.7,117837,DB01394,Colchicine
,9211992,distribution volumes,"During short experimental times (in situ brain perfusion technique), a comparable enhancement was found (4.26-fold): mean distribution volumes of colchicine were enhanced from 0.23 +/- 0.17 to 0.98 +/- 0.19 microl/g for the eight gray areas, and no effect was observed in the choroid plexus, which do not express P-gp.",Role of P-170 glycoprotein in colchicine brain uptake. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9211992/),[μl] / [g],0.23,118629,DB01394,Colchicine
,9211992,distribution volumes,"During short experimental times (in situ brain perfusion technique), a comparable enhancement was found (4.26-fold): mean distribution volumes of colchicine were enhanced from 0.23 +/- 0.17 to 0.98 +/- 0.19 microl/g for the eight gray areas, and no effect was observed in the choroid plexus, which do not express P-gp.",Role of P-170 glycoprotein in colchicine brain uptake. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9211992/),[μl] / [g],0.98,118630,DB01394,Colchicine
,8983937,peak levels,"Irrespective of the formulation used, the drug was rapidly absorbed from the gastrointestinal tract, peak levels of about 17 ng/ml being detected within 1 h in most subjects.","Comparative pharmacokinetics and bioavailability of two oral formulations of thiocolchicoside, a GABA-mimetic muscle relaxant drug, in normal volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983937/),[ng] / [ml],17,121541,DB01394,Colchicine
,8983937,MRT,"Elimination was rapid, with mean MRT values of 5-6 h.","Comparative pharmacokinetics and bioavailability of two oral formulations of thiocolchicoside, a GABA-mimetic muscle relaxant drug, in normal volunteers. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983937/),h,5-6,121542,DB01394,Colchicine
,8983937,oral bioavailability,"Relative to the tablet formulation, the oral bioavailability of the capsule formulation was 1.06 +/- 0.39.","Comparative pharmacokinetics and bioavailability of two oral formulations of thiocolchicoside, a GABA-mimetic muscle relaxant drug, in normal volunteers. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8983937/),,1.06,121543,DB01394,Colchicine
,11999759,flow rate,"The plasma samples were extracted with ethyl acetate and separated on a Phenomenex Luna C18(2) 5 microm, 150x2 mm column with a mobile phase consisting of acetonitrile-0.005% formic acid (350:650, v/v) at a flow rate of 0.35 ml/min.",Highly specific and sensitive liquid chromatography-tandem mass spectrometry method for the determination of 3-desmethylthiocolchicine in human plasma as analyte for the assessment of bioequivalence after oral administration of thiocolchicoside. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11999759/),[ml] / [min],0.35,132281,DB01394,Colchicine
,11999759,recovery,"The mean recovery for 3-desmethylthiocolchicine was 70%, with a lower limit of quantification set at 0.39 ng/ml.",Highly specific and sensitive liquid chromatography-tandem mass spectrometry method for the determination of 3-desmethylthiocolchicine in human plasma as analyte for the assessment of bioequivalence after oral administration of thiocolchicoside. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11999759/),%,70,132282,DB01394,Colchicine
,8161719,terminal half-life (t1/2 beta),"Serum thiocolchicoside concentrations showed an absorption phase followed by a biexponential decay with a terminal half-life (t1/2 beta) of approximately 5 h, similar for the three formulations.",Single-dose bioavailability of oral and intramuscular thiocolchicoside in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8161719/),h,5,132928,DB01394,Colchicine
,8161719,relative bioavailability,"The relative bioavailability of both oral formulations was approximately 25%, compared to the intramuscular formulation.",Single-dose bioavailability of oral and intramuscular thiocolchicoside in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8161719/),%,25,132929,DB01394,Colchicine
,23298502,Cmax,"An exception occurred with once-daily colchicine, whereby mean Cmax for colchicine was higher in patients 4 to less than 6 years (9.4 ng/mL) compared with the younger and older age groups (6.1-6.7 ng/mL).",Pharmacokinetics of colchicine in pediatric and adult patients with familial Mediterranean fever. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23298502/),[ng] / [ml],9.4,135856,DB01394,Colchicine
,23298502,Cmax,"An exception occurred with once-daily colchicine, whereby mean Cmax for colchicine was higher in patients 4 to less than 6 years (9.4 ng/mL) compared with the younger and older age groups (6.1-6.7 ng/mL).",Pharmacokinetics of colchicine in pediatric and adult patients with familial Mediterranean fever. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23298502/),[ng] / [ml],6.1-6.7,135857,DB01394,Colchicine
,21699389,K(c),Our phase-solubility data indicated the formation of a stable complex with K(c) ~0.31 mM(-1) at pH 7.4.,Inclusion complex of colchicine in hydroxypropyl-β-cyclodextrin tenders better solubility and improved pharmacokinetics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21699389/),1/[mM],0.31,143248,DB01394,Colchicine
,22760659,oral bioavailability,"Both compounds had favorable drug-like properties, and acceptable oral bioavailability (21-50 %) in mice, rats, and dogs.",Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22760659/),%,21-50,149424,DB01394,Colchicine
,9217274,unbound col,The SDZ PSC 833 treatment resulted in important modifications of colchicine blood pharmacokinetics: the unbound colchicine blood concentration at steady-state was enhanced from 149.6 +/- 9.9 to 333.5 +/- 81.7 ng/ml indicating a two-fold decrease in colchicine clearance.,"Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine. ",CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9217274/),[ng] / [ml],149.6,150215,DB01394,Colchicine
,9217274,blood concentration at steady-state,The SDZ PSC 833 treatment resulted in important modifications of colchicine blood pharmacokinetics: the unbound colchicine blood concentration at steady-state was enhanced from 149.6 +/- 9.9 to 333.5 +/- 81.7 ng/ml indicating a two-fold decrease in colchicine clearance.,"Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9217274/),[ng] / [ml],149.6,150216,DB01394,Colchicine
,9217274,blood concentration at steady-state,The SDZ PSC 833 treatment resulted in important modifications of colchicine blood pharmacokinetics: the unbound colchicine blood concentration at steady-state was enhanced from 149.6 +/- 9.9 to 333.5 +/- 81.7 ng/ml indicating a two-fold decrease in colchicine clearance.,"Effect of the P-glycoprotein inhibitor, SDZ PSC 833, on the blood and brain pharmacokinetics of colchicine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9217274/),[ng] / [ml],333.5,150217,DB01394,Colchicine
,9927383,lung edema clearance,DA increased lung edema clearance in room air breathing rats (from 0.50 +/- 0.02 to 0.75 +/- 0.06 ml/h) and in rats exposed to 100% O2 (from 0.28 +/- 0.03 to 0. 67 +/- 0.03 ml/h).,Dopamine restores lung ability to clear edema in rats exposed to hyperoxia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9927383/),[ml] / [h],0.50,151070,DB01394,Colchicine
,9927383,lung edema clearance,DA increased lung edema clearance in room air breathing rats (from 0.50 +/- 0.02 to 0.75 +/- 0.06 ml/h) and in rats exposed to 100% O2 (from 0.28 +/- 0.03 to 0. 67 +/- 0.03 ml/h).,Dopamine restores lung ability to clear edema in rats exposed to hyperoxia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9927383/),[ml] / [h],0.75,151071,DB01394,Colchicine
,9927383,lung edema clearance,DA increased lung edema clearance in room air breathing rats (from 0.50 +/- 0.02 to 0.75 +/- 0.06 ml/h) and in rats exposed to 100% O2 (from 0.28 +/- 0.03 to 0. 67 +/- 0.03 ml/h).,Dopamine restores lung ability to clear edema in rats exposed to hyperoxia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9927383/),[ml] / [h],0.28,151072,DB01394,Colchicine
,9927383,lung edema clearance,DA increased lung edema clearance in room air breathing rats (from 0.50 +/- 0.02 to 0.75 +/- 0.06 ml/h) and in rats exposed to 100% O2 (from 0.28 +/- 0.03 to 0. 67 +/- 0.03 ml/h).,Dopamine restores lung ability to clear edema in rats exposed to hyperoxia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9927383/),[ml] / [h],0. 67,151073,DB01394,Colchicine
,12698501,CI,"In the presence of Solutol HS 15, colchicine clearance (CI) was significantly decreased and its maximum plasma concentration (c(max)) was significantly increased as compared to the control group (CI: 15.6+/-7.0 ml/min/kg vs 34.3+/-2.3 ml/min/kg; c(max) 3055.1+/-587.4 h vs 1260.1+/-223.7 h; p<0.05).",Impact of Solutol HS 15 on the pharmacokinetic behaviour of colchicine upon intravenous administration to male Wistar rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12698501/),[ml] / [kg·min],15.6,153792,DB01394,Colchicine
,12698501,CI,"In the presence of Solutol HS 15, colchicine clearance (CI) was significantly decreased and its maximum plasma concentration (c(max)) was significantly increased as compared to the control group (CI: 15.6+/-7.0 ml/min/kg vs 34.3+/-2.3 ml/min/kg; c(max) 3055.1+/-587.4 h vs 1260.1+/-223.7 h; p<0.05).",Impact of Solutol HS 15 on the pharmacokinetic behaviour of colchicine upon intravenous administration to male Wistar rats. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12698501/),[ml] / [kg·min],34.3,153793,DB01394,Colchicine
,12698501,c(max),"In the presence of Solutol HS 15, colchicine clearance (CI) was significantly decreased and its maximum plasma concentration (c(max)) was significantly increased as compared to the control group (CI: 15.6+/-7.0 ml/min/kg vs 34.3+/-2.3 ml/min/kg; c(max) 3055.1+/-587.4 h vs 1260.1+/-223.7 h; p<0.05).",Impact of Solutol HS 15 on the pharmacokinetic behaviour of colchicine upon intravenous administration to male Wistar rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12698501/),h,3055.1,153794,DB01394,Colchicine
,12698501,c(max),"In the presence of Solutol HS 15, colchicine clearance (CI) was significantly decreased and its maximum plasma concentration (c(max)) was significantly increased as compared to the control group (CI: 15.6+/-7.0 ml/min/kg vs 34.3+/-2.3 ml/min/kg; c(max) 3055.1+/-587.4 h vs 1260.1+/-223.7 h; p<0.05).",Impact of Solutol HS 15 on the pharmacokinetic behaviour of colchicine upon intravenous administration to male Wistar rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12698501/),h,1260.1,153795,DB01394,Colchicine
,12698501,volume of distribution (V(d),"By contrast, there was no statistically significant difference but a trend to lower values only in the volume of distribution (V(d) 13.3+/-2.2 l/h vs 31.4+/-17.7 l/h, p=0.35).",Impact of Solutol HS 15 on the pharmacokinetic behaviour of colchicine upon intravenous administration to male Wistar rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12698501/),[l] / [h],13.3,153796,DB01394,Colchicine
,12698501,volume of distribution (V(d),"By contrast, there was no statistically significant difference but a trend to lower values only in the volume of distribution (V(d) 13.3+/-2.2 l/h vs 31.4+/-17.7 l/h, p=0.35).",Impact of Solutol HS 15 on the pharmacokinetic behaviour of colchicine upon intravenous administration to male Wistar rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12698501/),[l] / [h],31.4,153797,DB01394,Colchicine
,12698501,t(1/2,0.21+/-0.02 h vs 0.20+/-0.03 h) and second phase (t(1/2 2ndphase).,Impact of Solutol HS 15 on the pharmacokinetic behaviour of colchicine upon intravenous administration to male Wistar rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12698501/),h,0.20,153798,DB01394,Colchicine
,12698501,clearance,"In vitro, in rat hepatocytes, the clearance of colchicine was significantly reduced at 0.003% Solutol HS 15 present in the incubation medium (0.86+/-0.15 microl/min/10(-6) cells vs 1.46+/-0.06 microl/min/10(-6) cells).",Impact of Solutol HS 15 on the pharmacokinetic behaviour of colchicine upon intravenous administration to male Wistar rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12698501/),[min·μl] / [(10)^6],0.86,153799,DB01394,Colchicine
,12698501,clearance,"In vitro, in rat hepatocytes, the clearance of colchicine was significantly reduced at 0.003% Solutol HS 15 present in the incubation medium (0.86+/-0.15 microl/min/10(-6) cells vs 1.46+/-0.06 microl/min/10(-6) cells).",Impact of Solutol HS 15 on the pharmacokinetic behaviour of colchicine upon intravenous administration to male Wistar rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12698501/),[min·μl] / [(10)^6],1.46,153800,DB01394,Colchicine
,8035398,apparent total colchicine clearance,"Patients with renal insufficiency had a mean +/- SD apparent total colchicine clearance of 0.168 +/- 0.063 l/h/kg, apparent volume of distribution of 4.56 +/- 1.64 l/kg and elimination half-life (t1/2) of 18.8 +/- 1.2 h.",Colchicine disposition in patients with familial Mediterranean fever with renal impairment. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8035398/),[l] / [h·kg],0.168,160373,DB01394,Colchicine
,8035398,apparent volume of distribution,"Patients with renal insufficiency had a mean +/- SD apparent total colchicine clearance of 0.168 +/- 0.063 l/h/kg, apparent volume of distribution of 4.56 +/- 1.64 l/kg and elimination half-life (t1/2) of 18.8 +/- 1.2 h.",Colchicine disposition in patients with familial Mediterranean fever with renal impairment. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8035398/),[l] / [kg],4.56,160374,DB01394,Colchicine
,8035398,elimination half-life (t1/2),"Patients with renal insufficiency had a mean +/- SD apparent total colchicine clearance of 0.168 +/- 0.063 l/h/kg, apparent volume of distribution of 4.56 +/- 1.64 l/kg and elimination half-life (t1/2) of 18.8 +/- 1.2 h.",Colchicine disposition in patients with familial Mediterranean fever with renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8035398/),h,18.8,160375,DB01394,Colchicine
,8035398,clearance,"Patients with FMF with normal kidney function had a mean clearance of 0.726 +/- 0.110 l/h/kg, volume of distribution of 4.87 +/- 2.05 l/kg and terminal t1/2 of 4.4 +/- 1.0 h.",Colchicine disposition in patients with familial Mediterranean fever with renal impairment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8035398/),[l] / [h·kg],0.726,160376,DB01394,Colchicine
,8035398,volume of distribution,"Patients with FMF with normal kidney function had a mean clearance of 0.726 +/- 0.110 l/h/kg, volume of distribution of 4.87 +/- 2.05 l/kg and terminal t1/2 of 4.4 +/- 1.0 h.",Colchicine disposition in patients with familial Mediterranean fever with renal impairment. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8035398/),[l] / [kg],4.87,160377,DB01394,Colchicine
,8035398,terminal t1/2,"Patients with FMF with normal kidney function had a mean clearance of 0.726 +/- 0.110 l/h/kg, volume of distribution of 4.87 +/- 2.05 l/kg and terminal t1/2 of 4.4 +/- 1.0 h.",Colchicine disposition in patients with familial Mediterranean fever with renal impairment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8035398/),h,4.4,160378,DB01394,Colchicine
,32078103,fraction absorbed,The in vivo contribution of P-gp is minimal for high permeable compounds owing to their fraction absorbed of nearly 1.0.,"Evaluation of the Role of P-glycoprotein (P-gp)-Mediated Efflux in the Intestinal Absorption of Common Substrates with Elacridar, a P-gp Inhibitor, in Rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32078103/),,1.0,161619,DB01394,Colchicine
,22847688,percentage recovery,"The mean percentage recovery (n = 3) for the low, middle and high quality control samples was 91.23 ± 1.88%, 90.36 ± 0.55% and 89.71 ± 0.21%, respectively.",A liquid chromatography/electrospray ionization tandem mass spectrometric method for quantification of asiatic acid from plasma: application to pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22847688/),%,91.23,164968,DB01394,Colchicine
,22847688,percentage recovery,"The mean percentage recovery (n = 3) for the low, middle and high quality control samples was 91.23 ± 1.88%, 90.36 ± 0.55% and 89.71 ± 0.21%, respectively.",A liquid chromatography/electrospray ionization tandem mass spectrometric method for quantification of asiatic acid from plasma: application to pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22847688/),%,90.36,164969,DB01394,Colchicine
,22847688,percentage recovery,"The mean percentage recovery (n = 3) for the low, middle and high quality control samples was 91.23 ± 1.88%, 90.36 ± 0.55% and 89.71 ± 0.21%, respectively.",A liquid chromatography/electrospray ionization tandem mass spectrometric method for quantification of asiatic acid from plasma: application to pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22847688/),%,89.71,164970,DB01394,Colchicine
,15312157,tmax,M1 appeared rapidly in plasma (tmax=1 h) and was eliminated with an apparent terminal half-life of 7.3 h.,New metabolic and pharmacokinetic characteristics of thiocolchicoside and its active metabolite in healthy humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312157/),h,1,168793,DB01394,Colchicine
,15312157,apparent terminal half-life,M1 appeared rapidly in plasma (tmax=1 h) and was eliminated with an apparent terminal half-life of 7.3 h.,New metabolic and pharmacokinetic characteristics of thiocolchicoside and its active metabolite in healthy humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312157/),h,7.3,168794,DB01394,Colchicine
,15312157,tmax,"In contrast, after intramuscular administration both active entities (TCC and M1) were present; TCC was rapidly absorbed (tmax=0.4 h) and eliminated with an apparent terminal half-life of 1.5 h.",New metabolic and pharmacokinetic characteristics of thiocolchicoside and its active metabolite in healthy humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312157/),h,0.4,168795,DB01394,Colchicine
,15312157,apparent terminal half-life,"In contrast, after intramuscular administration both active entities (TCC and M1) were present; TCC was rapidly absorbed (tmax=0.4 h) and eliminated with an apparent terminal half-life of 1.5 h.",New metabolic and pharmacokinetic characteristics of thiocolchicoside and its active metabolite in healthy humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312157/),h,1.5,168796,DB01394,Colchicine
,15312157,apparent terminal half-life,M1 concentration peaked at 5 h and this metabolite was eliminated with an apparent terminal half-life of 8.6 h.,New metabolic and pharmacokinetic characteristics of thiocolchicoside and its active metabolite in healthy humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312157/),h,8.6,168797,DB01394,Colchicine
,15312157,relative oral,"As TCC and M1 present an equipotent pharmacological activity, the relative oral pharmacological bioavailability of TCC vs. intramuscular administration was calculated and represented 25%.",New metabolic and pharmacokinetic characteristics of thiocolchicoside and its active metabolite in healthy humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15312157/),%,25,168798,DB01394,Colchicine
,17624029,tumour-to-plasma ratio,"The tumour-to-plasma ratio was 0.6:1 at 0.25 h and increased to 6:1 at 48 h, indicating that drug-related material persisted in the tumour longer than in plasma.",Distribution of radioactivity and metabolite profiling in tumour and plasma following intravenous administration of a colchicine derivative (14C-ZD6126) to tumour-bearing mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17624029/),,0.6:1,172343,DB01394,Colchicine
,17624029,tumour-to-plasma ratio,"The tumour-to-plasma ratio was 0.6:1 at 0.25 h and increased to 6:1 at 48 h, indicating that drug-related material persisted in the tumour longer than in plasma.",Distribution of radioactivity and metabolite profiling in tumour and plasma following intravenous administration of a colchicine derivative (14C-ZD6126) to tumour-bearing mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17624029/),,6:1,172344,DB01394,Colchicine
,17827928,flow-rate,"After single-step deproteinization by acetonitrile using berberine hydrochloride as an internal standard (I.S.), solutes were separated on a Diamonsil C(18) column (250 mm x 4.6 mm I.D., 5 microm particle size) (Dikma), using acetonitrile-0.15% phosphoric acid solution (27:73, v/v) as mobile phase (flow-rate 1.0 ml/min); wavelength of the UV detector was set at 350 nm.",Determination of colchicine in mouse plasma by high performance liquid-chromatographic method with UV detection and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17827928/),[ml] / [min],1.0,188754,DB01394,Colchicine
,17827928,retention times,"The retention times for COL and I.S. were 11.23 min and 8.82 min, respectively.",Determination of colchicine in mouse plasma by high performance liquid-chromatographic method with UV detection and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17827928/),min,11.23,188755,DB01394,Colchicine
,17827928,retention times,"The retention times for COL and I.S. were 11.23 min and 8.82 min, respectively.",Determination of colchicine in mouse plasma by high performance liquid-chromatographic method with UV detection and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17827928/),min,8.82,188756,DB01394,Colchicine
,17827928,limit of detection,The limit of quantification was evaluated to be 1.5 ng/ ml and the limit of detection was 0.5 ng/ml.,Determination of colchicine in mouse plasma by high performance liquid-chromatographic method with UV detection and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17827928/),[ng] / [ml],0.5,188757,DB01394,Colchicine
,8047810,peak concentration,"A single oral dose of 1 mg colchicine led to a mean peak concentration of 3.60 +/- 1.04 ng/ml at a peak time of 2.16 +/- 0.34 h and a mean area under the plasma concentration time curve, extrapolated from time 0 to infinity, of 24.90 +/- 8.47 ng.h/ml.",Plasma kinetics and biliary excretion of colchicine in patients with chronic liver disease after oral administration of a single dose and after long-term treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8047810/),[ng] / [ml],3.60,194293,DB01394,Colchicine
,8047810,peak time,"A single oral dose of 1 mg colchicine led to a mean peak concentration of 3.60 +/- 1.04 ng/ml at a peak time of 2.16 +/- 0.34 h and a mean area under the plasma concentration time curve, extrapolated from time 0 to infinity, of 24.90 +/- 8.47 ng.h/ml.",Plasma kinetics and biliary excretion of colchicine in patients with chronic liver disease after oral administration of a single dose and after long-term treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8047810/),h,2.16,194294,DB01394,Colchicine
,8047810,area under the plasma concentration time curve,"A single oral dose of 1 mg colchicine led to a mean peak concentration of 3.60 +/- 1.04 ng/ml at a peak time of 2.16 +/- 0.34 h and a mean area under the plasma concentration time curve, extrapolated from time 0 to infinity, of 24.90 +/- 8.47 ng.h/ml.",Plasma kinetics and biliary excretion of colchicine in patients with chronic liver disease after oral administration of a single dose and after long-term treatment. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8047810/),[h·ng] / [ml],24.90,194295,DB01394,Colchicine
,8047810,Distribution half-life,"Distribution half-life was 2.83 +/- 0.74 h, and terminal plasma half-life was 9.81 +/- 2.08 h; the mean apparent volume of distribution and the mean apparent plasma clearance were 1448 +/- 4061 and 175.3 +/- 47.6 1/h, respectively.",Plasma kinetics and biliary excretion of colchicine in patients with chronic liver disease after oral administration of a single dose and after long-term treatment. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8047810/),h,2.83,194296,DB01394,Colchicine
,8047810,terminal plasma half-life,"Distribution half-life was 2.83 +/- 0.74 h, and terminal plasma half-life was 9.81 +/- 2.08 h; the mean apparent volume of distribution and the mean apparent plasma clearance were 1448 +/- 4061 and 175.3 +/- 47.6 1/h, respectively.",Plasma kinetics and biliary excretion of colchicine in patients with chronic liver disease after oral administration of a single dose and after long-term treatment. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8047810/),h,9.81,194297,DB01394,Colchicine
,8047810,apparent volume of distribution,"Distribution half-life was 2.83 +/- 0.74 h, and terminal plasma half-life was 9.81 +/- 2.08 h; the mean apparent volume of distribution and the mean apparent plasma clearance were 1448 +/- 4061 and 175.3 +/- 47.6 1/h, respectively.",Plasma kinetics and biliary excretion of colchicine in patients with chronic liver disease after oral administration of a single dose and after long-term treatment. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8047810/),[1] / [h],1448,194298,DB01394,Colchicine
,8047810,apparent plasma clearance,"Distribution half-life was 2.83 +/- 0.74 h, and terminal plasma half-life was 9.81 +/- 2.08 h; the mean apparent volume of distribution and the mean apparent plasma clearance were 1448 +/- 4061 and 175.3 +/- 47.6 1/h, respectively.",Plasma kinetics and biliary excretion of colchicine in patients with chronic liver disease after oral administration of a single dose and after long-term treatment. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8047810/),[1] / [h],175.3,194299,DB01394,Colchicine
,8047810,concentrations,Colchicine concentrations in bile (2025 +/- 1368 ng/ml) were clearly higher than in plasma.,Plasma kinetics and biliary excretion of colchicine in patients with chronic liver disease after oral administration of a single dose and after long-term treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8047810/),[ng] / [ml],2025,194300,DB01394,Colchicine
,34086100,Tmax,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),min,5,204525,DB01394,Colchicine
,34086100,Cmax,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),,1489.5,204526,DB01394,Colchicine
,34086100,systemic bioavailability (F,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),,118.65,204527,DB01394,Colchicine
,34086100,AUC,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),,"35,921.75",204528,DB01394,Colchicine
,34086100,half-life,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),min,30.92,204529,DB01394,Colchicine
,34086100,Tmax,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),min,15,204530,DB01394,Colchicine
,34086100,Cmax,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),,56.29,204531,DB01394,Colchicine
,34086100,F,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),,4.39,204532,DB01394,Colchicine
,34086100,AUC,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),,1663.79,204533,DB01394,Colchicine
,34086100,t1/2,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),,13.48,204534,DB01394,Colchicine
,34086100,Kel (,"Nasal liposomal rivastigmine formulation showed the best pharmacokinetic features with rapid onset of action (Tmax = 5 min), higher Cmax (1489.5 ± 620.71), enhanced systemic bioavailability (F = 118.65 ± 23.54; AUC = 35,921.75 ± 9559.46), increased half-life (30.92 ± 8.38 min), and reduced clearance rate (Kel (1/min) = 0.0224 ± 0.006) compared to oral rivastigmine (Tmax = 15 min; Cmax = 56.29 ± 27.05; F = 4.39 ± 1.82; AUC = 1663.79 ± 813.54; t1/2 = 13.48 ± 5.79; Kel (1/min) = 0.0514 ± 0.023).",Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34086100/),[1] / [min],0.0514,204535,DB01394,Colchicine
,2633927,"area under the plasma concentration-time curve (AUC-1, AUC-3)","The mean area under the plasma concentration-time curve (AUC-1, AUC-3) was calculated as 23.95 +/- 12.10 (AUC-1) and 26.73 +/- 12.75 (AUC-3) h.ng/ml after application of A and 28.01 +/- 14.74 (AUC-1) and 31.57 +/- 16.58 (AUC-3) h.ng/ml after application of B, respectively.",Pharmacokinetics/bioavailability of colchicine in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633927/),[h·ng] / [ml],23.95,205537,DB01394,Colchicine
,2633927,"area under the plasma concentration-time curve (AUC-1, AUC-3)","The mean area under the plasma concentration-time curve (AUC-1, AUC-3) was calculated as 23.95 +/- 12.10 (AUC-1) and 26.73 +/- 12.75 (AUC-3) h.ng/ml after application of A and 28.01 +/- 14.74 (AUC-1) and 31.57 +/- 16.58 (AUC-3) h.ng/ml after application of B, respectively.",Pharmacokinetics/bioavailability of colchicine in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633927/),[h·ng] / [ml],26.73,205538,DB01394,Colchicine
,2633927,AUC-3,"The mean area under the plasma concentration-time curve (AUC-1, AUC-3) was calculated as 23.95 +/- 12.10 (AUC-1) and 26.73 +/- 12.75 (AUC-3) h.ng/ml after application of A and 28.01 +/- 14.74 (AUC-1) and 31.57 +/- 16.58 (AUC-3) h.ng/ml after application of B, respectively.",Pharmacokinetics/bioavailability of colchicine in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633927/),[h·ng] / [ml],26.73,205539,DB01394,Colchicine
,2633927,AUC-1,"The mean area under the plasma concentration-time curve (AUC-1, AUC-3) was calculated as 23.95 +/- 12.10 (AUC-1) and 26.73 +/- 12.75 (AUC-3) h.ng/ml after application of A and 28.01 +/- 14.74 (AUC-1) and 31.57 +/- 16.58 (AUC-3) h.ng/ml after application of B, respectively.",Pharmacokinetics/bioavailability of colchicine in healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633927/),[h·ng] / [ml],28.01,205540,DB01394,Colchicine
,2633927,AUC-3,"The mean area under the plasma concentration-time curve (AUC-1, AUC-3) was calculated as 23.95 +/- 12.10 (AUC-1) and 26.73 +/- 12.75 (AUC-3) h.ng/ml after application of A and 28.01 +/- 14.74 (AUC-1) and 31.57 +/- 16.58 (AUC-3) h.ng/ml after application of B, respectively.",Pharmacokinetics/bioavailability of colchicine in healthy male volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633927/),[h·ng] / [ml],31.57,205541,DB01394,Colchicine
,2633927,peak plasma concentrations,Mean peak plasma concentrations of 4.15 +/- 2.35 (A) and 4.88 +/- 3.90 (B) ng/ml were reached at 1.15 +/- 0.38 (A) and 1.13 +/- 0.42 (B) h after application.,Pharmacokinetics/bioavailability of colchicine in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633927/),[ng] / [ml],4.15,205542,DB01394,Colchicine
,2633927,peak plasma concentrations,Mean peak plasma concentrations of 4.15 +/- 2.35 (A) and 4.88 +/- 3.90 (B) ng/ml were reached at 1.15 +/- 0.38 (A) and 1.13 +/- 0.42 (B) h after application.,Pharmacokinetics/bioavailability of colchicine in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633927/),[ng] / [ml],4.88,205543,DB01394,Colchicine
,2633927,terminal half-lives,The mean terminal half-lives accounted for 9.31 +/- 3.98 (A) and 10.57 +/- 5.53 (B) h.,Pharmacokinetics/bioavailability of colchicine in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633927/),h,9.31,205544,DB01394,Colchicine
,2633927,terminal half-lives,The mean terminal half-lives accounted for 9.31 +/- 3.98 (A) and 10.57 +/- 5.53 (B) h.,Pharmacokinetics/bioavailability of colchicine in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633927/),h,10.57,205545,DB01394,Colchicine
,2633927,total clearance (Cl/F),"The mean total clearance (Cl/F) and volume of distribution (V/F) were found to be 40.12 +/- 20.87 (A) and 46.58 +/- 24.65 (B) l/h and 472.59 +/- 196.46 (A) and 624.89 +/- 304.09 (B) l, respectively.",Pharmacokinetics/bioavailability of colchicine in healthy male volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633927/),[l] / [h],40.12,205546,DB01394,Colchicine
,2633927,volume of distribution (V/F),"The mean total clearance (Cl/F) and volume of distribution (V/F) were found to be 40.12 +/- 20.87 (A) and 46.58 +/- 24.65 (B) l/h and 472.59 +/- 196.46 (A) and 624.89 +/- 304.09 (B) l, respectively.",Pharmacokinetics/bioavailability of colchicine in healthy male volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633927/),[l] / [h],46.58,205547,DB01394,Colchicine
,2633927,volume of distribution (V/F),"The mean total clearance (Cl/F) and volume of distribution (V/F) were found to be 40.12 +/- 20.87 (A) and 46.58 +/- 24.65 (B) l/h and 472.59 +/- 196.46 (A) and 624.89 +/- 304.09 (B) l, respectively.",Pharmacokinetics/bioavailability of colchicine in healthy male volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633927/),l,624.89,205548,DB01394,Colchicine
,2633927,total amount excreted in urine,The mean total amount excreted in urine (Ae) was 172.66 +/- 91.51 (A) and 174.85 +/- 63.53 (B) micrograms.,Pharmacokinetics/bioavailability of colchicine in healthy male volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633927/),μg,172.66,205549,DB01394,Colchicine
,2633927,total amount excreted in urine,The mean total amount excreted in urine (Ae) was 172.66 +/- 91.51 (A) and 174.85 +/- 63.53 (B) micrograms.,Pharmacokinetics/bioavailability of colchicine in healthy male volunteers. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2633927/),μg,174.85,205550,DB01394,Colchicine
,30887253,bioavailability,"After single oral administration of LL01 at a dose of 10 mg/kg in SD male rats, LL01 showed acceptable PK properties with a mean bioavailability of 41%.",Tubulin colchicine site binding agent LL01 displays potent antitumor efficiency both in vitro and in vivo with suitable drug-like properties. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30887253/),%,41,214159,DB01394,Colchicine
,8930773,area under the concentration-time curve (AUC),"After intravenous bolus injection of colchicine, the area under the concentration-time curve (AUC) was 61.2 +/- 12.7 ng.hr/mL, steady-state volume of distribution (Vss) was 419 +/- 95 L, systemic clearance (Cl) was 8.5 +/- 1.8 L/hr, and the terminal half-life (t1/2) was 57.8 +/- 10.7 hours.",Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930773/),[h·ng] / [ml],61.2,232695,DB01394,Colchicine
,8930773,steady-state volume of distribution (Vss),"After intravenous bolus injection of colchicine, the area under the concentration-time curve (AUC) was 61.2 +/- 12.7 ng.hr/mL, steady-state volume of distribution (Vss) was 419 +/- 95 L, systemic clearance (Cl) was 8.5 +/- 1.8 L/hr, and the terminal half-life (t1/2) was 57.8 +/- 10.7 hours.",Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930773/),l,419,232696,DB01394,Colchicine
,8930773,systemic clearance (Cl),"After intravenous bolus injection of colchicine, the area under the concentration-time curve (AUC) was 61.2 +/- 12.7 ng.hr/mL, steady-state volume of distribution (Vss) was 419 +/- 95 L, systemic clearance (Cl) was 8.5 +/- 1.8 L/hr, and the terminal half-life (t1/2) was 57.8 +/- 10.7 hours.",Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930773/),[l] / [h],8.5,232697,DB01394,Colchicine
,8930773,terminal half-life (t1/2),"After intravenous bolus injection of colchicine, the area under the concentration-time curve (AUC) was 61.2 +/- 12.7 ng.hr/mL, steady-state volume of distribution (Vss) was 419 +/- 95 L, systemic clearance (Cl) was 8.5 +/- 1.8 L/hr, and the terminal half-life (t1/2) was 57.8 +/- 10.7 hours.",Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930773/),h,57.8,232698,DB01394,Colchicine
,8930773,peak plasma concentrations (Cmax),"After oral administration in solution form, peak plasma concentrations (Cmax) of 6.50 +/- 1.03 ng/mL were reached at time (tmax) 1.07 +/- 0.55 hours, with a rate of 0.109 +/- 0.024 hr-1 (Cmax/AUC); bioavailability was 47 +/- 14%.",Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930773/),[ng] / [ml],6.50,232699,DB01394,Colchicine
,8930773,time (tmax),"After oral administration in solution form, peak plasma concentrations (Cmax) of 6.50 +/- 1.03 ng/mL were reached at time (tmax) 1.07 +/- 0.55 hours, with a rate of 0.109 +/- 0.024 hr-1 (Cmax/AUC); bioavailability was 47 +/- 14%.",Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930773/),h,1.07,232700,DB01394,Colchicine
,8930773,rate,"After oral administration in solution form, peak plasma concentrations (Cmax) of 6.50 +/- 1.03 ng/mL were reached at time (tmax) 1.07 +/- 0.55 hours, with a rate of 0.109 +/- 0.024 hr-1 (Cmax/AUC); bioavailability was 47 +/- 14%.",Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930773/),1/[h],0.109,232701,DB01394,Colchicine
,8930773,Cmax/AUC,"After oral administration in solution form, peak plasma concentrations (Cmax) of 6.50 +/- 1.03 ng/mL were reached at time (tmax) 1.07 +/- 0.55 hours, with a rate of 0.109 +/- 0.024 hr-1 (Cmax/AUC); bioavailability was 47 +/- 14%.",Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930773/),1/[h],0.109,232702,DB01394,Colchicine
,8930773,bioavailability,"After oral administration in solution form, peak plasma concentrations (Cmax) of 6.50 +/- 1.03 ng/mL were reached at time (tmax) 1.07 +/- 0.55 hours, with a rate of 0.109 +/- 0.024 hr-1 (Cmax/AUC); bioavailability was 47 +/- 14%.",Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8930773/),%,47,232703,DB01394,Colchicine
,17236823,run time,"Colchicine and the internal standard (I.S.), tegafur, were extracted from the matrix with n-hexane:dichloromethane:isopropanol (300:150:15, v/v/v) and separated by reversed-phase high-performance liquid chromatography (HPLC) using formic acid:10 mM ammonium acetate:methanol (1:49:75, v/v/v) as the mobile phase in a run time of 2.5 min.",Rapid and sensitive liquid chromatography-tandem mass spectrometry method for the quantitation of colchicine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17236823/),min,2.5,237729,DB01394,Colchicine
,12404883,aque,"The aqueous solubility of colchicine was about 16.7 mg/ml, and the increase in solubility in the presence of 1% surfactant 1 or surfactant 2 to about 20.5 and 18.5 mg/ml was not considered to significantly affect the oral bioavailability.",Improvement of the bioavailability of colchicine in rats by co-administration of D-alpha-tocopherol polyethylene glycol 1000 succinate and a polyethoxylated derivative of 12-hydroxy-stearic acid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404883/),[mg] / [ml],16.7,239555,DB01394,Colchicine
,12404883,solubility,"The aqueous solubility of colchicine was about 16.7 mg/ml, and the increase in solubility in the presence of 1% surfactant 1 or surfactant 2 to about 20.5 and 18.5 mg/ml was not considered to significantly affect the oral bioavailability.",Improvement of the bioavailability of colchicine in rats by co-administration of D-alpha-tocopherol polyethylene glycol 1000 succinate and a polyethoxylated derivative of 12-hydroxy-stearic acid. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404883/),[mg] / [ml],16.7,239556,DB01394,Colchicine
,12404883,solubility,"The aqueous solubility of colchicine was about 16.7 mg/ml, and the increase in solubility in the presence of 1% surfactant 1 or surfactant 2 to about 20.5 and 18.5 mg/ml was not considered to significantly affect the oral bioavailability.",Improvement of the bioavailability of colchicine in rats by co-administration of D-alpha-tocopherol polyethylene glycol 1000 succinate and a polyethoxylated derivative of 12-hydroxy-stearic acid. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404883/),[mg] / [m],20.5,239557,DB01394,Colchicine
,12404883,solubility,"The aqueous solubility of colchicine was about 16.7 mg/ml, and the increase in solubility in the presence of 1% surfactant 1 or surfactant 2 to about 20.5 and 18.5 mg/ml was not considered to significantly affect the oral bioavailability.",Improvement of the bioavailability of colchicine in rats by co-administration of D-alpha-tocopherol polyethylene glycol 1000 succinate and a polyethoxylated derivative of 12-hydroxy-stearic acid. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12404883/),[mg] / [m],18.5,239558,DB01394,Colchicine
,7957521,distribution half-life (t1/2 lambda 1),"The first distribution half-life (t1/2 lambda 1) was short: 9.2 min in healthy volunteers and 3.0 min in the elderly group; the second distribution half-life (t1/2 lambda 2) was of the same order for both groups, 1.2 h.",Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957521/),min,9.2,239758,DB01394,Colchicine
,7957521,distribution half-life (t1/2 lambda 1),"The first distribution half-life (t1/2 lambda 1) was short: 9.2 min in healthy volunteers and 3.0 min in the elderly group; the second distribution half-life (t1/2 lambda 2) was of the same order for both groups, 1.2 h.",Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957521/),min,3.0,239759,DB01394,Colchicine
,7957521,distribution half-life (t1/2 lambda 2),"The first distribution half-life (t1/2 lambda 1) was short: 9.2 min in healthy volunteers and 3.0 min in the elderly group; the second distribution half-life (t1/2 lambda 2) was of the same order for both groups, 1.2 h.",Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957521/),h,1.2,239760,DB01394,Colchicine
,7957521,Plasma elimination half-lives,Plasma elimination half-lives were also in the same range: 30 h for healthy volunteers versus 34 h for the elderly subjects.,Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957521/),h,30,239761,DB01394,Colchicine
,7957521,Plasma elimination half-lives,Plasma elimination half-lives were also in the same range: 30 h for healthy volunteers versus 34 h for the elderly subjects.,Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957521/),h,34,239762,DB01394,Colchicine
,7957521,Mean residence time,Mean residence time was also in the same range in the two groups: 27 h in healthy volunteers and 21 h for elderly subjects.,Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957521/),h,27,239763,DB01394,Colchicine
,7957521,Mean residence time,Mean residence time was also in the same range in the two groups: 27 h in healthy volunteers and 21 h for elderly subjects.,Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957521/),h,21,239764,DB01394,Colchicine
,7957521,volume of distribution (Vz),"The volume of distribution (Vz) was 6.7 l.kg-1 for the healthy group and 6.3 l.kg-1 for the elderly group, while Vss was smaller: 4.2 l.kg-1 for healthy volunteers and 2.9 l.kg-1 for elderly subjects.",Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957521/),[l] / [kg],6.7,239765,DB01394,Colchicine
,7957521,volume of distribution (Vz),"The volume of distribution (Vz) was 6.7 l.kg-1 for the healthy group and 6.3 l.kg-1 for the elderly group, while Vss was smaller: 4.2 l.kg-1 for healthy volunteers and 2.9 l.kg-1 for elderly subjects.",Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957521/),[l] / [kg],6.3,239766,DB01394,Colchicine
,7957521,Vss,"The volume of distribution (Vz) was 6.7 l.kg-1 for the healthy group and 6.3 l.kg-1 for the elderly group, while Vss was smaller: 4.2 l.kg-1 for healthy volunteers and 2.9 l.kg-1 for elderly subjects.",Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957521/),[l] / [kg],4.2,239767,DB01394,Colchicine
,7957521,Vss,"The volume of distribution (Vz) was 6.7 l.kg-1 for the healthy group and 6.3 l.kg-1 for the elderly group, while Vss was smaller: 4.2 l.kg-1 for healthy volunteers and 2.9 l.kg-1 for elderly subjects.",Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957521/),[l] / [kg],2.9,239768,DB01394,Colchicine
,7957521,Total body clearance,Total body clearance was 10.5 l.h-1 for healthy and 5.5 l.h-1 for elderly subjects.,Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957521/),[l] / [h],10.5,239769,DB01394,Colchicine
,7957521,Total body clearance,Total body clearance was 10.5 l.h-1 for healthy and 5.5 l.h-1 for elderly subjects.,Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957521/),[l] / [h],5.5,239770,DB01394,Colchicine
,7957521,lag-time,"After oral administration of 1 mg, lag-time was 14 min in healthy volunteers and 11 min in elderly subjects.",Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957521/),min,14,239771,DB01394,Colchicine
,7957521,lag-time,"After oral administration of 1 mg, lag-time was 14 min in healthy volunteers and 11 min in elderly subjects.",Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957521/),min,11,239772,DB01394,Colchicine
,7957521,Maximal plasma concentration,Maximal plasma concentration was 5.5 ng.,Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957521/),ng,5.5,239773,DB01394,Colchicine
,7957521,Cmax,"ml-1 at 62 min in the healthy group, while in the elderly group Cmax was 12 ng.",Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957521/),ng,12,239774,DB01394,Colchicine
,7957521,absolute bioavailability,"Mean absolute bioavailability of the tablet was the same in both groups, 44% for healthy volunteers and 45% for elderly subjects.",Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957521/),%,44,239775,DB01394,Colchicine
,7957521,absolute bioavailability,"Mean absolute bioavailability of the tablet was the same in both groups, 44% for healthy volunteers and 45% for elderly subjects.",Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7957521/),%,45,239776,DB01394,Colchicine
,19822461,flow rate,"LC separation was successfully accomplished on a Waters RP8 Symmetryshield column (3.0mmx150mm, i.d., 5microm) with a gradient mobile phase of methanol (0.1% formic acid, v/v) and water (20mM ammonium acetate) at a flow rate 0.8mLmin(-1).","Development of a rapid and sensitive LC-MS/MS assay for the determination of combretastatin A4 phosphate, combretastatin A4 and combretastatin A4 glucuronide in beagle dog plasma and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19822461/),1/[mlmin],0.8,243485,DB01394,Colchicine
,19822461,accumulation ratio,"After daily intravenous drop infusions at 1mgkg(-1) for 7 consecutive days, the accumulation ratio was approximately 1.0, indicating no accumulation from multiple doses in beagles.","Development of a rapid and sensitive LC-MS/MS assay for the determination of combretastatin A4 phosphate, combretastatin A4 and combretastatin A4 glucuronide in beagle dog plasma and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19822461/),,1.0,243486,DB01394,Colchicine
,17067838,Absorption,"Absorption after oral ingestion varies widely (from 24% to 88% of the dose), the volume of distribution is extremely large (7 l/kg), and binding to albumin is moderate.",Colchicine today. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17067838/),%,24,255924,DB01394,Colchicine
,17067838,volume,"Absorption after oral ingestion varies widely (from 24% to 88% of the dose), the volume of distribution is extremely large (7 l/kg), and binding to albumin is moderate.",Colchicine today. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17067838/),[l] / [kg],7,255925,DB01394,Colchicine
,17067838,elimination half-life,Colchicine is excreted chiefly through the liver and has an elimination half-life of 20-40 hours.,Colchicine today. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17067838/),h,20-40,255926,DB01394,Colchicine
,8525161,bioavailability,"Following oral route, colchicine bioavailability is extremely variable (from 24 to 88% of the administered dose), the distribution volume is elevated (7 l/kg) but the binding to albumin is moderate.",[Colchicine: recent data on pharmacokinetics and clinical pharmacology]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525161/),%,24 to 88,265747,DB01394,Colchicine
,8525161,distribution volume,"Following oral route, colchicine bioavailability is extremely variable (from 24 to 88% of the administered dose), the distribution volume is elevated (7 l/kg) but the binding to albumin is moderate.",[Colchicine: recent data on pharmacokinetics and clinical pharmacology]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525161/),[l] / [kg],7,265748,DB01394,Colchicine
,8525161,elimination half-life,Colchicine elimination occurred mainly via hepatic pathways and the elimination half-life ranged from 20 to 40 hours.,[Colchicine: recent data on pharmacokinetics and clinical pharmacology]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8525161/),h,20 to 40,265749,DB01394,Colchicine
,1361141,distribution half-lives,"The first, in three patients, admitted early, showed a bi-exponential plasma colchicine decrease, with distribution half-lives of 30, 45 and 90 min.","Toxicokinetics of colchicine in humans: analysis of tissue, plasma and urine data in ten cases. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361141/),min,30,266376,DB01394,Colchicine
,1361141,distribution half-lives,"The first, in three patients, admitted early, showed a bi-exponential plasma colchicine decrease, with distribution half-lives of 30, 45 and 90 min.","Toxicokinetics of colchicine in humans: analysis of tissue, plasma and urine data in ten cases. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361141/),min,45,266377,DB01394,Colchicine
,1361141,distribution half-lives,"The first, in three patients, admitted early, showed a bi-exponential plasma colchicine decrease, with distribution half-lives of 30, 45 and 90 min.","Toxicokinetics of colchicine in humans: analysis of tissue, plasma and urine data in ten cases. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361141/),min,90,266378,DB01394,Colchicine
,1361141,Plasma terminal half-lives,Plasma terminal half-lives ranged from 10.6 to 31.7 h for both groups.,"Toxicokinetics of colchicine in humans: analysis of tissue, plasma and urine data in ten cases. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361141/),h,10.6 to 31.7,266379,DB01394,Colchicine
,1361141,renal clearance,"The fraction of unchanged colchicine excreted in urine was about 30%, renal clearance was about 13 l h-1 and three-fold less than total body clearance (39 l h-1).","Toxicokinetics of colchicine in humans: analysis of tissue, plasma and urine data in ten cases. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361141/),[l] / [h],13,266380,DB01394,Colchicine
,1361141,total body clearance,"The fraction of unchanged colchicine excreted in urine was about 30%, renal clearance was about 13 l h-1 and three-fold less than total body clearance (39 l h-1).","Toxicokinetics of colchicine in humans: analysis of tissue, plasma and urine data in ten cases. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361141/),[l] / [h],39,266381,DB01394,Colchicine
,1361141,apparent volume of distribution,The apparent volume of distribution was 21 l kg-1.,"Toxicokinetics of colchicine in humans: analysis of tissue, plasma and urine data in ten cases. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1361141/),[l] / [kg],21,266382,DB01394,Colchicine
,9052420,terminal elimination half-life,The terminal elimination half-life was prolonged (range 18-73.5 h).,Phase I trial and pharmacokinetics of the tubulin inhibitor 1069C85--a synthetic agent binding at the colchicine site designed to overcome multidrug resistance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9052420/),h,18-73.5,269150,DB01394,Colchicine
